TOP2A Informations sur la molécule
Molecule Name
Topoisomerase (DNA) II alpha
Alias de la molécule
TOP2A,TOP2,DNA topoisomerase 2-alpha,DNA topoisomerase II,alpha isozyme
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
EC:5.6.2.2，EC 5.6.2.2，TOP2A，DNA topoisomerase 2-alpha，DNA topoisomerase II， alpha isozyme，DNA Topoisomerase II Alpha，Topoisomerase (DNA) II Alpha 170kDa，TOP2，DNA Topoisomerase (ATP-Hydrolyzing)，DNA Topoisomerase II， 170 KD，EC 5.99.1.3，TP2A，DNA Gyrase
Contexte de la molécule
DNA topoisomerase 2-alpha (TOP2A) is also known as DNA topoisomerase II, alpha isozyme and TOP2. It is a topoisomerase which control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation. Also it is the targets of anti-cancer drugs that cause treatment-related leukemias with balanced translocations.
TOP2A Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Novobiocin Sodium | Phase 1 Clinical | Bacterial Infections; Neoplasms; Solid tumours | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Etoposide phosphate | BMY-40481 | Approved | Bristol-Myers Squibb Company | Etopophos | United States | Lymphoma, Non-Hodgkin; Multiple Myeloma; Testicular Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hodgkin Disease; Small Cell Lung Carcinoma | Cheplapharm Arzneimittel Gmbh | 1996-05-17 | Adrenocortical Carcinoma; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; CNS Embryonal Tumor; Germinoma; Hodgkin Disease; Kidney Neoplasms; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Gonadal Tissue; Neoplasms, Plasma Cell; Neuroblastoma; Neutropenia; Ovarian Neoplasms; Plasmacytoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Sarcoma, Ewing; Small Cell Lung Carcinoma; Solid tumours; Testicular Neoplasms; Thrombocytopenia; Uterine Cervical Neoplasms | Details |